HLB Science Appoints Kim Sujeong as New Head of Research Institute

[Asia Economy Reporter Chunhee Lee] HLB Science announced on the 16th that it has appointed Dr. Sujeong Kim, an expert in clinical trials and regulatory approval, as its new head of research.

Dr. Sujeong Kim, the new head of research, earned her master's degree from Pohang University of Science and Technology (POSTECH) and her doctorate from Hanyang University College of Medicine. She also served as an adjunct professor at Hanyang University Graduate School of Biomedical Science and Engineering. She has participated in antibiotic and anticancer drug development at domestic pharmaceutical and biotech companies such as Komipharm, CrystalGenomics, and PharmaResearch.

In particular, having conducted antibiotic clinical development and global clinical regulatory approval for controlling resistant strains, she is considered the ideal candidate for the clinical development of HLB Science's new drug candidate 'DD-S052P,' which is characterized by efficient inhibition of gram-negative bacteria and endotoxin neutralization mechanisms. Dr. Kim has also been involved in anticancer drug development research for various solid tumors, including glioblastoma (a type of brain cancer), liver cancer, and prostate cancer.

Through the recruitment of Dr. Kim, HLB Science aims to support the clinical management of 'DD-S052P' for sepsis and gram-negative superbug infections, which is currently underway after receiving approval for Phase 1 clinical trial plans from the French National Agency for the Safety of Medicines and Health Products (ANSM) in July last year, and plans to expand clinical trials to the European region in the future. DD-S052P is a treatment for sepsis and gram-negative superbug infections developed by HLB Science.

Yoon Jongseon, CEO of HLB Science, said, “With the recruitment of Dr. Sujeong Kim, we will be able to accelerate not only antibiotic development, which is our main focus, but also anticancer drug development, which is being promoted as a new business. We will pursue rapid clinical progress as well as strategies for collaboration with multinational pharmaceutical companies and technology export.”